Dosing dilemmas in obese children.

Area of Science:

• Pharmacology
• Pediatrics
• Obesity Research

Background:

• Childhood obesity presents challenges in determining appropriate drug dosages.
• Physiological changes in obese children can alter drug pharmacokinetics and pharmacodynamics.
• Limited clinical data exist on the impact of obesity on drug disposition and clearance in pediatric populations.

Purpose of the Study:

• To highlight the difficulties in establishing optimal drug doses for obese children.
• To emphasize the need for better data and guidance on pediatric pharmacotherapy in obesity.
• To propose strategies for improving drug dosing in this population.

Main Methods:

• Review of existing literature on pharmacokinetics and pharmacodynamics in obese children.
• Identification of data gaps in clinical studies evaluating drug dosing in pediatric obesity.
• Discussion of the role of physiologically based pharmacokinetic modeling.

Main Results:

• Assumptions about altered drug distribution and clearance in obese children lack robust clinical validation.
• Clinical studies on drug effects in obesity are often limited by poor design and small sample sizes.
• Drug development studies rarely include obese pediatric subjects.

Conclusions:

• Drug manufacturers should incorporate obese children into clinical studies and utilize pharmacokinetic modeling to inform dosing guidelines.
• Current dosing for many pediatric drugs in obese children relies on empirical experience and the precautionary principle.
• Validated body size descriptors are needed for bedside drug dose selection in obese children.